ScreenerHero

IMMPImmutep Ltd.

NAS · US · Healthcare · Biotechnology · immutep.com
0.3861USDMkt Cap: 56.90M $P/E: —

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod al…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap56.90M $
Enterprise Value-40.06M $
Revenue (TTM)7.92M $
Gross Profit-74.78M $
Net Income (TTM)-83.92M $
Revenue/Share0.0500 USD
Last Price0.3861 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINAU000000IMM6
Valuation
P/E (Trailing)—
P/E (Forward)-1.96
PEG—
EV/EBITDA0.49
EV/Revenue-5.06
P/S7.27
P/B0.82
EPS (TTM)-0.37
EPS (Forward)-0.20
52W Range
0.382321% of range0.4000
52W High0.4000 USD
52W Low0.3823 USD
Profitability
Gross Margin0.00%
Oper. Margin-763.71%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.85%
ROA-32.10%
Growth
Revenue Growth91.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-62.15M $
CapEx (TTM)932.37K $
FCF Margin-450.33%
FCF Yield-62.70%
Net Debt-97.92M $
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity0.01
Current Ratio2.97
Quick Ratio2.91
Book Value/Sh0.4741 USD
Cash/Share0.6730 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 28, 2016
Splits
Last Split3:10
Split DateDec 28, 2016
Analyst Consensus
Rating—
Target (Mean)1.500 USD
Upside (mean)+288.5%
Target Range1.500 USD – 1.500 USD
# Analysts1
Ownership
Shares Out.147.37M
Float143.03M
Insiders0.01%
Institutions1.13%
Short Interest
Short Ratio3.7d
Short % Float0.83%
Short % Out.0.81%
Shares Short1.20M
Short (prev mo.)3.90M
Technical
SMA 500.3962 (-2.5%)
SMA 2001.369 (-71.8%)
Beta2.19
S&P 52W Chg21.00%
Avg Vol (30d)113.89K
Avg Vol (10d)99.95K
Technical Indicators
RSI (14)46.9
MACD-0.0038
MACD Signal-0.0054
MACD Hist.+0.0016
BB Upper0.3996 USD
BB Middle0.3863 USD
BB Lower0.3730 USD
BB Width6.89%
ATR (14)0.0232 USD
Vol Ratio (20d)0.86x